Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• BGB-A317 (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Peripheral T Cell Lymphoma, PTCL | Phase 2 | Status: COMPLETED | Results posted: 2022-05-04